直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

IP Update

Supreme Court Decides to Hear Two New Patent Cases

October 9, 2012

By Erika Harmon Arner

As the U.S. Supreme Court begins its 2012 October term, the Court added two new patent-related cases to its docket. In Bowman v. Monsanto Corp., No. 11-796, the Court will consider the extent of patent rights in the sale of genetically altered seeds. In particular, the Court will examine whether Monsanto’s sale of seeds exhausts any rights to a second generation of those seeds. The Federal Circuit rejected Bowman’s call for a “robust” exhaustion doctrine that encompasses the progeny of seeds and other self-replicating biotechnologies, finding that each new generation of seeds is a newly infringing article subject to Monsanto’s patent rights.

In Gunn v. Minton, No. 11-1118, the Court will examine federal jurisdiction in patent malpractice cases. The Texas Supreme Court, applying a U.S. Supreme Court multi-prong test in this area, found that federal courts have exclusive jurisdiction over malpractice cases where a patent issue is a necessary, disputed, and substantial element of the malpractice claim. A dissent at the Texas Court argued the patent issue in question was not “disputed” or “substantial.” The dissent further claimed that this decision upset the balance between federal and state courts by locking all patent malpractice decisions in federal courts and providing precedent to improperly remove state jurisdiction over malpractice actions that implicate federal issues.

 

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Related Industries

Chemical

Energy

Life Sciences

Biotechnology

Related Professionals

Erika Harmon Arner
Partner
Washington, DC
+1 571 203 2754
Email

Copyright © Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP